Литература. 
Современный взгляд на лечение системной красной волчанки

1. Иванова М. М. Системная красная волчанка. Диагностика и лечение. Клин. Ревматология, 1995, 1, 220.

2. Gladman D.D., Urowitz M.B. Duboiss Lupus erythematosus. 5th Ed. Eds D.J.Waalace, B.H. Hahn, Baltimore, 1997, 12 131 228.

3. Соловьев С. К., Иванова М. М., Насонов Е. Л. Интенсивная терапия ревматических заболеваний. Издательство «МИК», Москва, 2001.

4. Насонов Е. Л. Противовоспалительная терапия ревматических болезней. Москва, издательство «МСИТИ», 1996, 169 181.

5. Насонов Е. Л., Штутман В. З., Насонова В. А. Перспективы применения циклоспорина, А при ревматических заболеваниях. Клин. Медицина, 1994, 5, 1219.

6. Blank M., BenBassat M., Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis and Rheumatism, 1992, 35, 11, 13 501 354.

7. Caccavo D., Lagana B., Mitterhofer A. et al. Longterm treatment of systemic lupus erythematosus with cyclosporine A. Arthritis and Rheumatism, 1997, 40 (1), 2735.

8. Cyclosporine. Clinical application in autoimmune diseases. Edited by David E. Yocum. MosbyWolfe, 2000.

9. Walter D.H., Haendeler J., Galle J. et al. Cyclosporine A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation, 1998, 98, 11 531 157.

10. Kingdon E.J., McLean A.G., Psimenou E. et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus, 2001, 10, 60 611.

11. Adu D., Cross J., Jayne DRW. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus, 2001, 10, 203 208.

12. Chan T.M., Li F.K., Tang C.S.O. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. The New England Journal of Medicine, 2000, 343 (16), 11 561 162.

13. Illei G.G., Klippel J.H. Novel approaches in the treatment of lupus nephritis. Lupus, 1998, 7, 644 648.

14. Stevens R.J., Andujar C., Edwards C.J. et al. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus experience in sixteen consecutive patients. Br.J.Rheumat., 1997, 36, 353 359.

15. Hirohata S., Ohnishi K., Sagawa A. Treatment of systemic lupus erythematosus with lobenzarit: an open clinical trial. Clin. And Exp. Rheumatol., 1994, 12, 261 265.

16. Strand V. Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. Current Opinion in Rheumatology, 1999, 11, 330 340.

17. Davis J.C., Manzi S., Yarboro C. et al. Recombinant human Dnase in patients with lupus nephritis. Lupus, 1999, 8, 6876.

18. Llorente L., GarciaPadilla C., RichaudPatin Y. et al. Treatment of systemic lupus erythematosus with an antiinterluken10 monoclonal antibody. Arthrit. Rheum., 1998 (suppl.), 41, S109.

19. Tyndall A., Passweg J., Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann.Rheum.Dis., 2001, 60, 702 707.

20. Vollenhoven R., Engleman E., McGuire J. Dehydroepiandrosterone in systemic lupus erythematosus. Arthr. Rheum., 1995, 38 (12), 18 261 831.

21. Mok C., Lau C.S., Ho CTK. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumat, 1998, 27, 342 346.

22. Sturgess A.D., Evans D.T., Mackay I. R, Riglar A. Effects of the estrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J.Clin.Lab.Immunol., 1984, 13, 1114.

23. Levin J., Markhan M.J., Greenwald E.S. et al. Effects of tamoxifen treatment on cortisol metabolism and the course of the disease in advanced brest cancer. Cancer, 1981, 47, 13 941 397.

24. Liberman M.E., Jordan V.C., Fritsch M. Direct and reversible inhibition of estradiol stimulated prolactin synthesis by antiestrogen in vitro. J.Biol. Chem., 1983, 258, 47 344 740.

25. Walker S.E., Allen S.H., Hoffman R.W. Prolactin a stimulator of disease activity in systemic lupus erythematosus. Lupus, 1995, 4, 39.

26. AlvarezNemegyei J., CovarrubiasCobos A., EscalanteTriay F. et al. Bromocriptine in systemic lupus erythematosus: a double blind, randomized placebo controlled study. Lupus, 1998, 7, 414 419.

27. Насонов Е. Л., Баранов А. А., Шилкина Н. П. Васкулиты и васкулопатии. Ярославль, «Верхняя Волга», 1999, 540 574.